The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment

Calcified Tissue International

Volumn 58, Issue 4, 1996, Pages 216-220

  Kraenzlin, M E ^a,b   Seibel, M J ^c   Trechsel, U ^d   Boerlin, V ^d   Azria, M ^d   Kraenzlin, C A ^a,b   Haas, H G ^a,b  

^a Endocrine Practice and Laboratory   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Sandoz Pharma Ltd   (Switzerland)

Author keywords

Biochemical markers; Bone metabolism; Calcitonin; Hydroxyproline; Menopause; Osteocalcin; Procollagen type I; Pyridinoline

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN; SALCATONIN;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0029871569     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02508638     Document Type: Article

References (36)

1. Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, Kraszewski A (1978) Comparative effects of oestrogen and a progestagen on bone loss in postmenopausal women. Clin Sci Mol Med 54:193-195
2. Lindsay R (1987) Prevention of osteoporosis. Clin Orthop Rel Res 222:44-59
3. Christiansen CK, Christensen MS, McNair P, Hagen C, Stocklund K, Transbol I (1980) Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273-279
4. Copp DH, Cameron EC, Cheney BA, Davidson AGF, Henze HK (1962) Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70: 638-649
5. Reginster J-Y (1991) Effect of calcitonin on bone mass and fracture rates. Am J Med 91 (suppl):5B19S-5B22S
6. Austin LA, Heath H (1981) Calcitonin: physiology and pathophysiology. N Engl J Med 304:269-278
7. Mazzuoli GF, Passeri M, Gennari M, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effect of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3-8
8. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 23:295-303
9. Overgaard K, Hansen MA, Nielsen V-AH, Riis BJ. Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 89:1-6
10. Reginster JY, Albert A, Lecart MP, Lambelin P, Denis D, Deroisy R, Fontaine MA, Franchimont P (1987) One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1481-1483
11. Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 199:477-479
12. Ljunghall S, Gärdsell P, Johnell O, Larsson K, Lindh E, Obrant K, Sernbo I (1991) Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 49:17-19
13. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. J Clin Invest 82:1268-1274
14. Haas HG, Liebrich BM, Schaffner W (1990) Calcitonin and osteoporosis-a critical reappraisal of the literature 1980-1989. Klin Wochenschr 68:359-371
15. Farley JR, Chestnut CH III, Baylink DJ (1981) Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin. Clin Chem 27:2002-2007
16. Bessey OA, Lowry OH, Brock MJ (1946) Method for rapid determination of alkaline phosphatase with 5 cubic millimeters of serum. J Biol Chem 164:321-329
17. Podenphant J, Larsen NE, Christiansen C (1984) An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 142:145-148
18. Woessner JF (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440-447
19. Black D, Duncan A, Robins SP (1989) Quantitative analysis of the pyrdinium crosslinks of collagen in urine using ionpaired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203
20. Seibel MJ, Duncan A, Robins SP (1989) Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J Rheumatol 16:964-970
21. Robins SP (1983) Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. J Biochem 215:167-173
22. Greenwood FC, Hunter W, Glover J (1963) Preparation of I-131 labelled human growth hormone of high specific radioactivity. Biochemistry 89:114-123
23. Gundry CR, Miller CW, Ramos E, Moscona A, Stein JA, Mazess RB, Sartoris DJ, Resnick D (1990) Dual-energy radiographic absorptiometry of the lumbar spine: clinical experience with two different systems. Radiology 174:539-541
24. Mazess R, Collick B, Trempe J, Barden H, Hanson J (1989) Performance evaluation of a dual-energy X-ray bone densitometer. Calcif Tissue Int 44:228-232
25. Pouilles J-M, Tremollieres F, Todorovsky N, Ribot C (1991) Precision and sensitivity of dual-energy x-ray absorptiometry in spinal osteoporosis. J Bone Miner Res 6:997-1002
26. Wahner HW, Dunn WL, Brown ML, Riggs BL (1988) Comparison of dual-energy X-ray absorptiometry and dual photon absorptiometry for bone mineral measurements of the lumbar spine. Mayo Clin Proc 63:1075-1084
27. Gennari C, Montagnani P, Nardi P, Zacchei F, Bigazzi C, Cepollaro C (1987) Long-term effect of cyclic or continuous calcitonin treatment on bone mass in established postmenopausal osteoporosis. Osteoporosis II 2:919-921
28. Gennari C, Agnusdei D, Cepollaro C, Zacchei F. Palmieri R (1987) Effect of intermittent or continuous long-term calcitonin nasal spray treatment on bone mass in established postmenopausal osteoporosis. Osteoporosis II 3:1323-1329
29. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R (1992) An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 50:381-383
30. Mazzuoli GF, Tabolli S, Bigi F, Valtorta C, Minisola S, Diacinti D, Scamecchia L, Bianchi G, Piolini M, Dell'Acqua S (1990) Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int 47:209-214
31. Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A (1992) Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 15:225-232
32. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331-2338
33. Woodhouse NJY, Mohamedally SM, Saed-Nejad F, Martin TJ (1977) Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. Br Med J 2:927-929
34. Reginster JY, Mautalen C, Gennari C (1987) Are antibodies against salmon calcitonin able to inhibit the biological efficacy of the drug? In: Osteoporosis 1987. Osteopress Aps, Copenhagen, Denmark, pp 916-918
35. Levy F, Muff R, Dotti-Siegrist S, Dambacher MA, Fischer JA (1988) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab 67:541-545
36. Reginster JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JL, Collette J, Franchimont P (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83-86